Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. Because of their unique capacity to form structural tissues, MSCs also being explored for use in 3D printing applications. [Read more…]
We Analyzed a Decade of Historical Information on Cord Blood & Cord Tissue Markets (This Is What We Learned)
The cord blood banking market is complex. There are regions experiencing growth and regions experiencing decline. There are extremely successful cord blood banks, and banks that are going out of business or being acquired by the competition.
In addition, there are unique opportunities occurring within the cord blood space that are based on emerging technologies, such as ex vivo expansion of cord blood.
The cord tissue market is also complex, although for different reasons. Today, half of all cord blood banks worldwide offer this service and the number is accelerating. Interestingly, the mesenchymal stem cells (MSCs) contained in cord tissue may have growing opportunities relative to the hematopoietic stem cells (HSCs) contained in cord blood, because MSCs just surpassed HSCs in the scientific literature for the first time in history.
For this reason, BioInformant is offering industry-leading market intelligence for both cord blood and cord tissue markets for the next 14 days only.
Act by Feb 29, 2016, and you can get two reports for the price of one, a savings of $3,795.
CORD BLOOD + CORD TISSUE PACKAGE:
- Complete 2015-16 Global Cord Blood Banking Industry Report
- Mesenchymal Stem Cells – Advances & Applications
This is an exclusive offer available only to BioInformant readers, so enter the coupon code “CordBloodCordTissue” during checkout (for either product) and you will automatically receive the other report for free.
To compete within the global cord blood banking market, you need to be informed about both cord blood and cord tissue markets. This is your opportunity to get a strategic edge.
Capitalizing on Mesenchymal Stem Cell Applications – Market Size, Segments, & Trends
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.
MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more. [Read more…]
Regenerative Medicine Bolsters Progress in Finding a Cure for Type 1 Diabetes
Dr. Bryan Laffitte, Director of Drug Discovery Pharmacology at the Genomics Institute of the Novartis Research Foundation, talks about progress his lab is making in producing an effective treatment for type 1 diabetes in the video below. Don’t miss key takeaways from the video at the end of this article!
Key Points Include:
- Type 1 diabetes is an inherited auto-immune disease in which the body destroys the pancreatic beta cells that create insulin, a hormone that regulates blood glucose levels
- Dr. Laffitte and his team research how to create more beta cells by determining what compounds cause these cells to divide and proliferate
- When these compounds were tested in trials involving animals with type 1 diabetes, their blood glucose levels and beta cell counts were properly restored!
- The next step for Dr. Laffitte’s lab will be testing the safety of these compounds for human use!
- A treatment utilizing regenerative medicine would be a serious aid for those with type 1 diabetes who must perform frequent and costly insulin injections routinely
Want to be better informed than your competition? Get future stem cell industry updates.
About Us
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.
Tissue Regenix Introduces Decellularized Pig Tendon as Scaffold for ACL Repair
Antony O’Dell, CEO of Tissue Regenix, discusses the success of the first clinical trial use of Tissue Regenix’s new technology for treating ruptures of the anterior cruciate ligament (ACL). Watch the video below, followed by key points.
Key Points Include:
- Last December, orthopedic and trauma surgeon, Dr. Gabriel Oliver, successfully implanted OrthoPure™ XT decellularised tendons using Tissue Regenix patented dCELL® technology in two patients who had suffered ACL tears during athletic activity
- These surgeries are the first in a clinical trial of 40 patients. The trial is a step toward securing regulatory sign-off for a 2017 launch of Tissue Regenix’s new technology
- dCELL technology uses tendons from pigs to create a “like for like” replacement for damaged tissue (in this case, a torn ACL) which is then repopulated by host cells
- With over 900,000 ACL surgeries being performed in the US and EU each year, the OrthoPure XT implants are a significant leap in surgical options for this very common sports injury
- Valued at $4.4 B, the ACL and meniscus global market presents huge opportunity for Tissue Regenix’s advancements in regenerative and sports medicine!
About Us
BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
- « Previous Page
- 1
- …
- 155
- 156
- 157
- 158
- 159
- …
- 194
- Next Page »